A Prospective, US-based Study Assessing Mogamulizumab-Ass...

Primary Objective:

To assess the incidence of mogamulizumab-associated
rash (MAR) and its association with overall response in patients with cutaneous T-cell lymphoma
(CTCL; mycosis fungoides [MF] and Sézary Syndrome [SS] subtypes) treated with mogamulizumab

Secondary Objectives:

To describe the characteristics and treatment patterns of MAR, and outcomes of MAR management protocol
To assess clinical outcomes (response, duration of response (DOR), progression free survival (PFS), and time to next significant lymphoma therapy (TTNL)) in
patients with CTCL treated with mogamulizumab in the real-world setting
To assess all serious adverse events (SAEs) of patients with CTCL treated with mogamulizumab in
the real-world setting.
To assess the association of MAR with DOR, TTNT and PFS

Exploratory Objectives:

To analyze the CTCL tumor microenvironment using paired single-cell RNA and T-cell receptor (TCR) analysis
To explore biomarkers that will predict clinical outcomes
To evaluate patient reported symptoms and quality of life

Clinical Trial Details